Arcutis Biotherapeutics, Inc. — Form 8-K Summary
Reporting date: December 22, 2021. The filing reports entry into a material loan agreement, related financial obligations, and FDA acceptance for review of the company’s NDA for roflumilast cream for psoriasis. The filing is not a periodic financial statement and does not provide current revenue, profit, cash flow, margin, or balance-sheet figures.
Business Context and Key Events
- Arcutis entered into a loan and security agreement with SLR Investment Corp. as collateral agent and the participating lenders.
- The FDA accepted the company’s NDA for roflumilast cream for treatment of psoriasis in adults and adolescents.
- The FDA assigned a PDUFA target action date of July 29, 2022.
Financing and Financial Obligations
- Total committed term-loan capacity is up to $225.0 million.
- The $75.0 million Tranche A Term Loan was funded on December 22, 2021.
- Additional availability consists of a $50.0 million Tranche B-1 loan, up to $75.0 million of Tranche B-2 loans, and up to $25.0 million of Tranche C loans.
- Tranche B borrowing requires satisfactory evidence of FDA approval of ARQ-151 for a plaque-psoriasis indication. Tranche C borrowing requires trailing six-month net product revenue of $110.0 million.
- Interest accrues at a floating annual rate equal to 7.45% plus the greater of 0.10% or the applicable one-month benchmark rate. Monthly interest payments begin February 1, 2022, following funding of a term loan.
- Outstanding principal is due January 1, 2027, unless repaid earlier.
- The company paid or owes a $1.0 million closing fee, a final fee equal to 6.95% of funded original principal, lenders’ expenses, and an exit fee generally equal to 3.0% of each funded term loan upon specified change-of-control or revenue-milestone events.
- The loans are secured by substantially all company assets, including intellectual property, subject to specified exceptions.
Material Changes, Covenants, and Risks
- This filing establishes significant secured debt financing; it does not present a prior comparable period or quantify period-over-period changes in operating results.
- Voluntary prepayments are subject to premiums of 3.0%, 2.0%, or 1.0%, depending on the timing of repayment.
- The agreement restricts additional indebtedness, liens, dividends, acquisitions, business changes, asset dispositions, mergers, and change-of-control transactions, among other activities.
- Beginning with the month ending December 31, 2023, the company must meet specified net-product-revenue thresholds unless its average market capitalization over the applicable trailing five-day period is at least $400.0 million.
- Events of default include payment or covenant breaches, certain legal proceedings, and a lender determination of material adverse change. Default interest increases the applicable rate by 4.0% annually, and lenders may accelerate the debt and enforce collateral remedies.
- Future borrowing under the facility depends on FDA approval and achievement of revenue milestones. The filing does not state the probability or timing of those milestones.
Guidance and Outlook
The filing provides no revenue, earnings, cash-flow, or commercial-launch guidance. The principal near-term regulatory milestone is the FDA’s July 29, 2022 PDUFA target date for the roflumilast cream NDA. The financing provides potential liquidity, but draws beyond Tranche A are conditional and the debt creates interest, fee, covenant, and collateral obligations.
Investor Verification Items
- Confirm the amount of Tranche A proceeds received and the company’s cash balance after the financing in subsequent periodic filings.
- Review the full loan agreement and redacted exhibits for the specific revenue-covenant thresholds, cure periods, collateral exceptions, and other restrictions.
- Track the FDA’s action on the roflumilast cream NDA and whether the conditions for Tranche B borrowing are satisfied.
- Verify any subsequent draws, interest expense, deferred financing costs, final fees, and exit-fee obligations.
- Assess liquidity and financing needs relative to the January 1, 2027 maturity date and the company’s ability to meet future revenue covenants.